A second-generation, self-amplifying COVID-19 Vaccine: World’s first approval and distribution in the Japanese market with vaccine hesitancy
The mRNA vaccine is a milestone in immunotherapeutics, as symbolized by the 2023 Nobel Prize for Physiology or Medicine awarded to Drs. Karikó and Weissman. Whereas the conventional, “first-generation” mRNA vaccine was globally distributed to hundreds of millions of people to decrease COVID-19 preva...
Saved in:
| Main Author: | Toshio Naito |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2025-12-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/21645515.2025.2530291 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
SARS-CoV-2 seroprevalence among healthcare workers in a highly vaccinated Japanese medical center from 2020–2023
by: Yan Yan, et al.
Published: (2024-12-01) -
Impact of COVID-19 vaccination status on hospitalization and disease severity: A descriptive study in Nagasaki Prefecture, Japan
by: Guoxi Cai, et al.
Published: (2024-12-01) -
Self-Amplifying RNA: Advantages and Challenges of a Versatile Platform for Vaccine Development
by: Thomas Vallet, et al.
Published: (2025-04-01) -
Development of mRNA rabies vaccines
by: Zixin Fang, et al.
Published: (2024-12-01) -
UK cancer vaccine advance – Recognising and realising opportunities
by: Charles Craddock, et al.
Published: (2025-01-01)